Live Analyst Rating Changes 28295 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Justin Walsh
JONE

Justin Walsh

Wall Street Analyst
★★★★☆
#723
on 13Foresight · ranked by our own returns
59%
Success Rate
+18.9%
Average Return
32 of 54 calls profitable · +15.3% vs benchmark
S&P 500 (SPY)
📈 Across the calls we could measure, roughly 59% of Justin Walsh's ratings turned a profit when each position was held for 1 year — averaging +18.9% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

122 Buy 10 Hold 0 Sell
Justin's Stock Coverage 37 ratings · 2026-08-28
Company Date Position Consensus Price Target 1-Yr Return vs S&P 500
SPTX
Seaport Therapeutics, Inc.
Aug 25, 2026 BUY Strong Buy
+41.6% avg upside
7 analysts
$32.00
23.29% Upside
· ·
RNXT
RenovoRx
Aug 19, 2026 BUY Strong Buy
+327.2% avg upside
5 analysts
$8.00
414.56% Upside
+12.6% ·
CLNN
Clene
Aug 18, 2026 BUY Strong Buy
+628.1% avg upside
11 analysts
$30.00
563.74% Upside
+5.6% ·
NMTC
NeuroOne Medical Technologies
Aug 18, 2026 BUY Strong Buy
+227.9% avg upside
5 analysts
$8.00
357.05% Upside
+8.0% ·
SER
Serina Therapeutics
Aug 18, 2026 BUY Strong Buy
+339.6% avg upside
3 analysts
$11.00
339.94% Upside
+9.5% ·
ATNM
Actinium Pharmaceuticals
Aug 14, 2026 BUY Strong Buy
+583.4% avg upside
11 analysts
$3.00
196.88% Upside
+5.8% ·
LNTH
Lantheus
Aug 14, 2026 HOLD Buy
-19.5% avg upside
21 analysts
-0.1% ·
CATX
Perspective Therapeutics
Aug 14, 2026 BUY Strong Buy
+248.1% avg upside
22 analysts
$18.00
480.69% Upside
-1.2% ·
DFTX
Definium Therapeutics
Aug 13, 2026 BUY Strong Buy
+18.6% avg upside
22 analysts
$90.00
113.14% Upside
-0.3% ·
TLSI
TriSalus Life Sciences
Aug 10, 2026 BUY Strong Buy
+99.1% avg upside
8 analysts
$11.00
133.84% Upside
-8.4% ·
PRAX
Praxis Precision Medicines
Aug 07, 2026 BUY Strong Buy
+51.0% avg upside
24 analysts
$441.00
24.88% Upside
+2.0% ·
RAPP
Rapport Therapeutics, Inc.
Aug 06, 2026 BUY Strong Buy
+14.7% avg upside
14 analysts
$50.00
1.14% Upside
+9.7% ·
XAIR
Beyond Air
Jul 31, 2026 HOLD Strong Buy
+1725.0% avg upside
10 analysts
-4.5% ·
BLRX
Bioline RX Ltd Sponsored ADR
Jul 31, 2026 HOLD Strong Buy
+247.6% avg upside
6 analysts
-0.4% ·
ATAI
Atai Beckley N.V.
Jul 16, 2026 HOLD Buy
+23.0% avg upside
17 analysts
+3.2% ·
ANRO
Alto Neuroscience, Inc.
Jun 26, 2026 BUY Strong Buy
-11.7% avg upside
13 analysts
$44.00
25.19% Upside
+34.1% ·
VNRX
VolitionRX
May 18, 2026 BUY Strong Buy
+1946.4% avg upside
11 analysts
$24.00
5288.37% Upside
-81.6% ·
ACHV
Achieve Life Sciences
May 12, 2026 BUY Strong Buy
+87.7% avg upside
15 analysts
$20.00
148.49% Upside
+36.4% ·
RADX
Radiopharm Theranostics Limited Sponsored ADR
Mar 25, 2026 BUY Strong Buy
+675.8% avg upside
6 analysts
$30.00
1032.12% Upside
-43.6% ·
VOR
Vor Biopharma
Jan 05, 2026 HOLD Buy
+87.5% avg upside
17 analysts
+120.8% ·
MNPR
Monopar Therapeutics Inc
May 14, 2025 HOLD Strong Buy
-9.6% avg upside
18 analysts
+64.3% ·
CNSY
Cerenome
Mar 21, 2025 HOLD Strong Buy
+937.2% avg upside
11 analysts
-78.8% ·
AU:RAD
Radiopharm Theranostics Limited
Oct 30, 2024 BUY Strong Buy
+4344.4% avg upside
1 analyst
$0.40
4344.39% Upside
+0.0% ·
PRME
Prime Medicine, Inc.
Aug 08, 2024 BUY Strong Buy
+167.0% avg upside
17 analysts
$20.00
473.02% Upside
-13.8% ·
QUCY
Quantum Cyber
Jun 04, 2024 BUY Buy
+172.1% avg upside
4 analysts
$4.00
172.13% Upside
+181.0% ·
CRIS
Curis
Jun 06, 2022 BUY Strong Buy
+762.6% avg upside
12 analysts
$10.00
549.43% Upside
· ·
GTBP
GT Biopharma
May 19, 2022 BUY Strong Buy
+3373.2% avg upside
3 analysts
$18.00
5852.37% Upside
· ·
HROW
Harrow Health
May 19, 2022 BUY Strong Buy
+40.3% avg upside
12 analysts
$20.00
46.79% Downside
+269.5% ·
CMPX
Compass Therapeutics
May 10, 2022 BUY Strong Buy
+283.1% avg upside
20 analysts
$10.00
306.60% Upside
+105.5% ·
CTSO
Cytosorbents
May 04, 2022 BUY Strong Buy
+3375.7% avg upside
13 analysts
$6.00
1775.06% Upside
+30.2% ·
ETON
Eton Pharmaceuticals
Apr 07, 2022 BUY Strong Buy
-39.7% avg upside
9 analysts
$10.00
83.33% Downside
-15.5% ·
VRAYQ
Viewray
Jan 11, 2022 BUY Strong Buy
+558333233.3% avg upside
12 analysts
$7.00
699999899.97% Upside
· ·
FOCL
FocalTherics
Nov 26, 2021 HOLD Buy
+95.7% avg upside
8 analysts
+93.5% ·
PGEN
Precigen
Nov 26, 2021 HOLD Strong Buy
+243.3% avg upside
11 analysts
-50.3% ·
SNDX
Syndax Pharmaceuticals
Nov 17, 2021 BUY Strong Buy
+74.4% avg upside
27 analysts
$30.00
53.32% Upside
+18.6% ·
ALP
Alpha Compute
Sep 02, 2021 BUY Strong Buy
+9662.4% avg upside
7 analysts
$40.00
23709.46% Upside
· ·
GERN
Geron
Feb 17, 2021 BUY Strong Buy
+180.0% avg upside
19 analysts
$4.00
164.05% Upside
-48.2% ·
🔒 32 more ratings — with price targets, crowd consensus and our measured returns.
Free account unlocks every analyst's full coverage table.
Justin Walsh — Frequently Asked Questions
How accurate are Justin Walsh's stock ratings?
Based on the calls 13Foresight could measure, about 59% of Justin's ratings were profitable over a one-year hold, with an average return of +18.9% per rating, or +15.3% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is Justin ranked on 13Foresight?
Justin Walsh is currently ranked #723 with a 4-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Justin cover?
Justin most recently has ratings on SPTX, RNXT, CLNN, NMTC, SER, ATNM, LNTH, CATX, DFTX, TLSI, PRAX, RAPP and 25 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.